ABSTRACT
The current meta-analysis was performed to investigate the association between non-metastatic protein 23 (NM23) expression, tumor pathology, and disease prognosis in colorectal cancer (CRC) among Asians. English and Chinese language-based electronic databases (e.g., PubMed, EBSCO, Ovid, Springerlink, Wiley, Web of Science, Wanfang databases, China National Knowledge Infrastructure, VIP databases) were searched using search terms to identify published studies relevant to NM23 and CRC with immunohistochemistry. In total, 289 studies were identified through database searches, and 16 cohort studies (4 studies in English, 12 in Chinese) were chosen for meta-analysis, which included 1592 CRC patients. The results revealed that NM23 protein expression in CRC tissue was higher in patients with Dukes stages A and B than in patients with Dukes stages C and D. The NM23 protein was expressed at higher levels in well- and moderately differentiated tumors than in poorly differentiated tumors. The 5-year survival rate was also higher in CRC patients with NM23-positive tumors than in CRC patients with NM23-negative tumors. Significantly, 5-year tumor relapse and metastasis were lower in patients with NM23-positive tumors than in CRC patients with NM23-negative tumors. The findings suggest that NM23 expression status is associated with tumor aggressiveness and survival in CRC among Asians. Importantly, CRC patients with NM23-positive tumors had a better prognosis, and thus NM23 expression maybe used as a key prognostic indicator for CRC.
Subject(s)
Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , NM23 Nucleoside Diphosphate Kinases/metabolism , Adenocarcinoma/epidemiology , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Asian People , China/epidemiology , Cluster Analysis , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/mortality , Disease Progression , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , NM23 Nucleoside Diphosphate Kinases/genetics , Neoplasm Grading , Odds Ratio , Prognosis , Publication BiasABSTRACT
The main pathological characteristic of osteoarthritis (OA) is cartilage damage. We explored cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase-3 (MMP-3) changes during articular cartilage injury and repair. Rabbits were randomly divided into the following: a blank control group; groups M1, M2, and M3, in which breaking was performed for 2, 4, and 6 weeks, respectively; and groups L1, L2, and L3, in which breaking was discontinued for 2, 4, and 6 weeks, respectively, following a 4-week recovery period. There are 7 rabbits in each group. The degree of cartilage damage in each group was scored (OA score). An enzyme-linked immunosorbent assay was used to detect COMP and MMP-3 levels in serum and joint fluid. The OA scores were 3.89 ± 2.31, 7.21 ± 2.31, and 10.88 ± 2.08 points in groups M1, M2, and M3, respectively (P < 0.05). COMP and MMP-3 levels were significantly higher in groups M1, M2, and M3 than in C. The OA score improved significantly following the 4-week recovery period (P < 0.05). COMP and MMP-3 levels began to decrease as the time following discontinuation of breaking increased, but were higher than in the control (P < 0.05). MMP- 3 and COMP levels were correlated with OA score (r > 0.7, P < 0.05). COMP and MMP-3 levels were correlated between joint fluid and serum (r = 0.899, r = 0.874, P < 0.05, respectively). Long-term joint breaking can cause articular cartilage damage. Doing some activites after the process can promote self-repair of articular cartilage. COMP and MMP-3 levels were associated with articular cartilage destruction and repair.
Subject(s)
Cartilage Oligomeric Matrix Protein/metabolism , Matrix Metalloproteinase 3/biosynthesis , Synovial Fluid/metabolism , Animals , Biomarkers/blood , Biomarkers/metabolism , Cartilage Oligomeric Matrix Protein/blood , Cartilage Oligomeric Matrix Protein/genetics , Cartilage, Articular/enzymology , Cartilage, Articular/metabolism , Cartilage, Articular/pathology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Glycoproteins/blood , Glycoproteins/metabolism , Male , Matrix Metalloproteinase 3/blood , Matrix Metalloproteinase 3/genetics , Osteoarthritis, Knee/blood , Osteoarthritis, Knee/genetics , Rabbits , Synovial Fluid/enzymology , TranscriptomeABSTRACT
The aim of this retrospective study was to evaluate the prognostic influence of lymphatic vessel invasion (LVI) in stage I non-small cell lung cancer (NSCLC) patients. From January 2004 to December 2007, LVI was detected in 57 patients with T1N0M0 NSCLC; therefore, 114 patients with the same pathology, T stage, and surgery method, but without LVI, were selected as the control group to compare survival. The overall survival and relapse-free survival rates were estimated using the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis. The average follow-up length was 59.94 ± 23.1 months. The 5-year overall survival rates of the LVI-negative and the LVI-positive groups were 90.54 and 70.1%, respectively (P = 0.002). A multivariate analysis revealed LVI to be an independent predictive factor (hazard ratio = 4.562; P = 0.004). The 5-year overall survival rates for patients who received postoperative adjunctive therapy and those who did not in the LVI-positive group were 88.2 and 61.5%, respectively, with a P value less than 0.05 in both univariate and multivariate analyses. LVI is a poor prognostic factor in stage I NSCLC patients; postoperative adjunctive therapy is needed to improve the prognosis of NSCLC patients with LVI.